Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital
Su H. Lei,
Alberto M. Borobia,
Antonio J. Carcas,
Background: The first generic PPI was introduced in Spain in 2001, and since then their prescriptions have increased steadily by about 200%. Aim: To evaluate the frequency of use and the appropriateness of indications of PPIs in hospitalised patients, and possible factors predicting their use. We also evaluated relevant PPI-drug interactions and serious adverse drug reactions (SADRs). Methods: This was a cross-sectional, prescription-indication drug-utilisation study in hospitalised patients with follow-up until discharge. Sampling was random and stratified by services, and was calculated to obtain an error in the precision of prescription of ±4% with a 95% confidence interval with maximum variability (50%). Results: 328 patients were included; 28.65% were prescribed a PPI at admission, 82.62% were prescribed a PPI during hospitalisation, and 54.75% at discharge, with inappropriate indications in 74.47%, 61.25% and 80.24% respectively. The OR of being discharged with PPIs was 3.01(95% CI:2.17 – 4.18, p=0.000). The inappropriate indication most frequently seen at admission and at discharge was antiplatelet therapy. During hospitalisation it was prophylaxis for stress ulcer in patients at low risk. PPI prescription at admission remained at discharge in 75.90% of cases, 73.02% without an acceptable indication. Being > 64 years old, taking > 4 drugs, co-medication (NSAIDs, antiaggregation and anticoagulation), certain hospital departments and length of stay > 15 days predicted 83.7% of prescriptions at discharge. Four relevant PPIdrug interactions were found, and 2 resulted in SADRs, thus the incidence per 1, 000 patients was 2.66 (Poisson 95% CI:0.62-7.23). Conclusions: There was a very high frequency of overuse of PPIs in inpatients and outpatients. Hospitalisation did not represent an opportunity for better prescription of PPIs.
Keywords: (4 A 6) Drug utilisation studies, drug use, drug-drug interactions, serious adverse drug reactions, proton pump inhibotors, overuse, SADRs, NSAIDs, antiaggregation, anticoagulation, Drug utilisation studies, omeprazole, gastric acid, C. Difficile, gastroenteritis, Campylobacter jejuni, acenoucumarol, clopidogrel, carbamazepine, cyclosporin, diazepam, digoxin, metamizole, nifedipine, phenytoin, tacrolimus, warfarin, Traumatology, Chronic renal disease, COPD, Hepatic disease, Hypertension, CHF, AIS, antiplatelet therapy, Relevant PPI-Drug Interactions, RDIs, GORD, UGIB, prophylaxis, H2RA, nosocomial pneumonia, H. Pylori
Rights & PermissionsPrintExport